Where Does Kidney Cancer Spread? Common Metastatic Sites

Kidney cancer, primarily renal cell carcinoma, spreads most often to the lungs, bones, liver, lymph nodes, brain, and adrenal glands. Roughly one in five patients already has metastatic disease at the time of diagnosis, and about half of those who undergo surgery to remove the kidney eventually develop metastases later on.¹ What makes kidney cancer distinctive among solid tumors is how unpredictably it travels, how late it can recur, and how differently each destination organ affects a patient’s outlook.

How Kidney Cancer Enters the Bloodstream

The kidneys sit in one of the most vascular neighborhoods in the body, and renal cell carcinoma exploits that blood supply aggressively. One of its unusual traits is a tendency to form tumor thrombus, where the cancer physically extends into a blood vessel. Between 4% and 10% of patients already have tumor growing into the renal vein or the large vein draining into the heart, the inferior vena cava, by the time they are diagnosed.² Once cancer cells are inside these major veins, they have a direct highway to the lungs and, from there, to the rest of the body.

There is also a less obvious route. A network of veins running alongside the spine, sometimes called the paravertebral venous plexus, allows blood to flow backward from the kidneys into the vertebral column without passing through the lungs first. Imaging studies have shown tumor within the small veins between vertebrae, providing evidence that this backward venous flow can seed spinal metastases directly.³⁴ This helps explain why solitary spine metastases sometimes appear even in patients whose lungs remain clear.

Lungs

The lungs are one of the most frequently affected sites in metastatic kidney cancer.⁵ This makes anatomical sense: venous blood leaving the kidney travels directly to the right side of the heart and then into the lung’s capillary beds, where circulating tumor cells can lodge and grow. Lung metastases from kidney cancer often appear as multiple round nodules on a chest CT scan. They may cause no symptoms at all or, if they grow large enough or involve the airways, lead to cough, shortness of breath, or occasionally coughing up blood.

The relatively good news about lung-only metastases is that they tend to carry a better prognosis than spread to most other organs. In selected patients with a small number of lung nodules, surgically removing the metastases can contribute to long-term survival, especially if the disease appeared some time after the original kidney surgery rather than at the same time as the primary tumor.⁵

Bones

About 30% of patients with kidney cancer develop bone metastases, making this the second most common destination after the lungs.⁶ What sets kidney cancer bone disease apart from many other cancers is how destructive it is. The metastases are highly osteolytic, meaning they eat away at bone rather than building up abnormal bone tissue.⁷ Research has identified specific proteins secreted by kidney cancer cells in bone that stimulate the formation and activation of osteoclasts, the cells that normally break down bone during remodeling. The result is extensive bone destruction that goes far beyond what most other tumor types produce.⁶

For patients, this translates into serious complications: severe bone pain, fractures that happen during normal activity, spinal cord compression from collapsing vertebrae, and dangerously high calcium levels in the blood as mineral leaches out of destroyed bone.⁸ The spine, pelvis, and long bones of the arms and legs are common locations. Because kidney cancer bone metastases are so vascular and bleed heavily, even a biopsy or surgical stabilization of a fracture requires careful planning. Bone-protecting medications can reduce the rate of these skeletal events, and this class of drug appears to work particularly well for kidney cancer compared to bone metastases from other tumor types.⁷

Liver

When kidney cancer reaches the liver, the prognosis tends to be more guarded than with lung or bone metastases. Timing matters a great deal here. In patients whose liver metastases were discovered at the same time as the primary kidney tumor, median survival after liver surgery was around one year. For those whose liver metastases appeared later, after the kidney had already been removed, median survival after liver surgery jumped to nearly six years.⁹ This gap illustrates a recurring theme in kidney cancer: disease that shows up simultaneously at multiple sites behaves more aggressively than disease that appears in a delayed, piecemeal fashion.

Newer interventional approaches, including targeted delivery of therapy directly into the liver’s blood supply, are being studied. Imaging-based measures of how tumors respond to these treatments have shown promise in distinguishing patients who will live significantly longer from those who will not.¹⁰

Brain

Brain metastases affect roughly 8% of patients starting treatment for metastatic kidney cancer.¹¹ This number may understate the true frequency because patients with brain involvement have historically been excluded from clinical trials, leaving this population understudied. The brain is something of a protected zone. The blood-brain barrier and the brain’s distinct immune environment can shield tiny tumor deposits from systemic drugs that work well elsewhere in the body, which means cancer can quietly persist in the brain even when scans show tumors shrinking everywhere else.¹²

Treatment choices make a real difference in outcomes for brain metastases. In a large international database, patients treated with immunotherapy-based combination regimens had a median survival of nearly 33 months, compared to about 21 months for those receiving older targeted drugs alone. Similarly, patients who received focused radiation treatments or neurosurgery to the brain lived significantly longer than those who received only whole-brain radiation or no local treatment at all.¹¹

Adrenal Glands and Lymph Nodes

The adrenal glands sit directly on top of each kidney, so spread to the adrenal gland on the same side can happen by direct extension of the tumor, not just through the blood. Whether the adrenal involvement is from direct growth versus blood-borne spread actually matters for staging and prognosis.¹³ Spread to the opposite adrenal gland, by contrast, is a clear sign of distant metastatic disease.

Lymph node involvement, while not always the first destination for kidney cancer, roughly doubles the risk of distant metastases down the line.¹ Interestingly, kidney cancer leans more heavily on blood vessel spread than lymphatic spread compared to many other cancers, which is part of why its metastatic pattern looks so different from, say, breast or colon cancer.

When Cancer Subtype Shapes Where It Goes

Not all kidney cancers are created equal, and the subtype significantly influences where the disease ends up. Clear cell renal cell carcinoma, which accounts for the vast majority of cases and more than 90% of metastatic kidney cancer, shows a stronger tendency to spread to the lungs and brain than other subtypes.¹¹⁴ Papillary kidney cancer, the second most common type, is less likely to go to bone but more likely to involve lymph nodes. Chromophobe kidney cancer, a rarer subtype, has a notably higher rate of liver metastases.¹⁴

Beyond the traditional subtypes defined under the microscope, molecular profiling is revealing even finer distinctions. Tumors with a strongly angiogenic molecular signature, meaning they are driven by blood vessel growth, are far more likely to send metastases to the pancreas and less likely to involve lymph nodes. Tumors with a proliferative signature, meaning they are driven by rapid cell division, show the opposite pattern: more lymph node disease and less pancreatic involvement.¹⁵ This kind of molecular mapping is beginning to explain why two patients with what looks like the same cancer under a microscope can have very different patterns of spread.

The Pancreas Paradox

Pancreatic metastases from kidney cancer deserve their own discussion because they behave nothing like metastases elsewhere. Patients whose kidney cancer spreads to the pancreas tend to do remarkably well, with survival times approaching a decade in recent studies.¹⁶ Researchers describe the biology as indolent, and the clinical course often follows an unusually favorable path compared to metastases at other sites.¹⁷ Despite longstanding awareness of this pattern, the biological explanation for why the pancreas seems to foster slower-growing kidney cancer deposits remains unclear. The molecular work linking angiogenic tumor profiles to pancreatic tropism may eventually fill in that gap, but for now it remains one of the more intriguing puzzles in cancer biology.

Unusual and Rare Destinations

Kidney cancer has a well-earned reputation for showing up in places where most cancers never go. Documented sites of metastasis include the orbit of the eye, the parotid gland in the jaw, paranasal sinuses, tongue, tonsils, thyroid, heart, skin, and skeletal muscle.¹⁸ These unusual presentations can confuse clinicians who are not thinking about a kidney primary, especially when the metastasis shows up years or even decades after the original kidney was removed. In fact, the first sign of kidney cancer in some patients is a strange mass in an unexpected location that turns out, on biopsy, to be renal cell carcinoma.

Late Recurrence and the Problem of Dormancy

Many cancers are considered cured if they have not returned within five years of surgery. Kidney cancer does not follow that rule. Late recurrences, defined as those appearing more than five years after kidney removal, are well documented and keep oncologists on alert far longer than for most other solid tumors. There are published case reports of metastases appearing more than 20 years after the primary surgery.¹⁹

The leading explanation is tumor dormancy: cancer cells that escaped the kidney before or during surgery, settled somewhere in the body, and then remained inactive for years before eventually waking up and growing. Why certain cells lie dormant and what triggers them to proliferate remains poorly understood. Risk factors that predict a higher chance of late recurrence include a more advanced stage of the original tumor, higher-grade disease, and evidence of tumor growing into blood or lymph vessels at the time of the initial surgery.²⁰ A scoring system based on these factors stratifies patients into low, intermediate, and high risk groups, with late recurrence rates ranging from about 3% to over 22%.²⁰ For higher-risk patients, surveillance imaging well beyond the five-year mark is standard practice.²¹

Detection and Imaging

Finding metastases early can change treatment options and outcomes. Conventional CT and MRI remain the workhorses for surveillance and staging of kidney cancer. For bone disease specifically, PET/CT scans using a sugar-based tracer outperform traditional bone scans in accuracy.²²

An emerging approach involves a type of PET scan originally developed for prostate cancer that targets a protein called PSMA, which is also expressed on the blood vessels feeding kidney tumors. In early studies of patients with metastatic clear cell kidney cancer, this PSMA-based PET/CT detected metastases at a rate of about 92%, compared to roughly 63% for standard CT and MRI.²³ The studies are small so far, but the gap in detection rates is striking enough that larger validation trials are underway. Better detection of small metastases could mean more patients are identified as candidates for focused treatments like surgery or stereotactic radiation while the disease is still limited.

When Metastases Can Be Treated Locally

Kidney cancer is one of the few solid tumors where surgically removing metastases is a routine consideration, not just a last resort. The concept of oligometastatic disease, where only a small number of metastatic sites exist, has become central to treatment planning. In a single-center study tracking patients over a decade, those who had their metastases surgically removed had significantly better overall survival than those treated with systemic drugs alone.²⁴ Stereotactic ablative radiotherapy, which delivers highly focused radiation to individual tumors, is increasingly used alongside or instead of surgery for metastases in locations where an operation is riskier, such as the brain or spine.²⁵

The decision about whether to pursue local treatment of metastases depends on several factors: how many sites are involved, whether the disease appeared at the same time as the primary tumor or years later, the specific subtype and grade, and how the cancer is responding to systemic therapy. The patients who benefit most tend to be those with a limited number of metastases that appeared after a long disease-free interval. This is where the distinction between synchronous and metachronous disease matters clinically. As noted earlier with liver metastases, late-appearing disease generally carries a much better prognosis than disease found at diagnosis.

Paraneoplastic Syndromes and Misleading Symptoms

Up to 20% of patients with kidney cancer experience paraneoplastic syndromes, symptoms caused not by the physical mass of the tumor but by substances the cancer secretes into the bloodstream.²⁶ These can include unexplained fevers, abnormal liver function tests even without liver metastases, high calcium levels, abnormal red blood cell counts, and a wasting syndrome. The tricky part is that some of these symptoms mimic what you would expect from metastatic spread, leading clinicians down the wrong diagnostic path. High calcium, for example, can be caused by bone metastases eating away at the skeleton or by the primary tumor pumping out a hormone-like protein, and the treatment implications differ substantially.

For some patients, a paraneoplastic syndrome is the first clue that something is wrong. Kidney tumors often grow silently, producing no urinary symptoms until they are quite large. A puzzling fever, unexpected anemia, or abnormal lab value sometimes leads to imaging that reveals a kidney mass. Most of these syndromes resolve once the cancer is removed or effectively treated, which can serve as both a treatment response marker and a source of reassurance.²⁶